GENE ONLINE|News &
Opinion
Blog

Mithra Submits Marketing Approval Application in Japan to Combat Dysmenorrhea

by Sinead Huang
Share To

Mithra Pharmaceuticals, a Belgian biotech company dedicated to Women’s Health, announced a significant development in its partnership with Fuji Pharma Co., Ltd. on October 23 as they submitted a marketing approval application for ESTELLE® in Japan. This strategic move is part of a broader mission to address dysmenorrhea, a common women’s health issue.

Related article: FDA Approves Astellas’ Non-hormonal Menopause Treatment After Extended Review

Building on a Strong Partnership

In 2016, Fuji Pharma secured commercialization rights for both ESTELLE® and DONESTA® in Japan and the ASEAN region, a market that could potentially reach 330 million patients. ESTELLE® features Mithra’s core asset, Estetrol (E4), a unique native estrogen produced during pregnancy, known for its selective action on estrogen receptors, minimal impact on the liver, and the coagulation cascade. This distinct profile positions E4 as a potential game-changer in the women’s health landscape, offering multiple advantages to patients.

Fuji Pharma’s application submission triggers an important milestone as Mithra is set to receive a EUR 2.5 million payment. The collaboration between the two companies has already yielded significant results. Fuji Pharma began selling the product in Thailand under the name NEXTSTELLIS™ in April 2023. This successful partnership further strengthens Mithra’s global presence and underscores its dedication to revolutionizing women’s health.

Addressing Dysmenorrhea – A Crucial Women’s Health Issue

Dysmenorrhea, commonly referred to as menstrual cramps, affects millions of women, with symptoms ranging from lower abdominal pain, back pain, and nausea to irritability and depression. Mithra’s proactive move is in response to the growing demand for innovative solutions. The global dysmenorrhea market, valued at €257 million (approximately $271 million) in 2022, reflects the pressing need for effective treatments. As Mithra takes significant steps in Japan, its mission to redefine women’s health gains momentum.

In conclusion, Mithra’s partnership with Fuji Pharma and the submission of the ESTELLE® marketing approval application in Japan represents a pivotal moment in the company’s journey. Their commitment to addressing women’s health challenges, such as dysmenorrhea, is reinforced by their ongoing collaborations and innovative solutions, and it sets the stage for potential breakthroughs in women’s health worldwide.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Inside the Exosome Boom: Global Experts Talk Industry Trends, Roadblocks, and What’s Next
2025-04-16
Tiny Packages, Big Promise: The Rise of Exosomes in Modern Medicine
2025-04-16
Researchers Create DNA Test to Tailor Treatment for Bacterial Vaginosis
2025-03-30
LATEST
World Vaccine Congress Washington 2025 Recap: Urgent Calls for Trust, Tech, and Global Access
2025-04-25
Astellas’ Transformation Journey: From Merger to Global Player, Betting on the Edge of Innovation and Risk?
2025-04-25
Roche Announces Massive 50 Billion Dollar Investment in the United States
2025-04-25
Steminent Stands Ready to Showcase Novel MSC-based Therapy for Spinocerebellar Ataxia at Global Stage
2025-04-24
Arkansas Medicaid Work Requirements Led to Coverage Loss for a Significant Number of Recipients
2025-04-24
Boehringer agrees new partnership to advance first-in-class precision cancer therapies
2025-04-24
Bristol Myers Squibb Schizophrenia Drug Fails Pivotal Test as an Add-On to Antipsychotics
2025-04-24
EVENT
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
2025-05-03
29th Taiwan Joint Cancer Conference 2025
Taipei, Taiwan
2025-05-05
Swiss Biotech Day 2025
Basel, Switzerland
2025-05-13
ASGCT 28th Annual Meeting 2025
New Orleans, U.S.A.
2025-05-30
ASCO Annual Meeting 2025
Chicago, U.S.A
2025-06-11
ISSCR 2025 Annual Meeting
Hong Kong
Scroll to Top